Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Bleeding Disorders

05 April 2016 European Medicines Agency Supports Maintaining Orphan Designation for IDELVION®

CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein]. IDELVION® is CSL Behring’s novel, long-acting recombinant albumin fusion protein for treating hemophilia B.

> Read More
21 March 2016 IDELVION® for Hemophilia B Now Available in the U.S.

CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting recombinant albumin fusion protein for treating hemophilia B, is now available nationwide.

> Read More
04 March 2016 U.S. FDA Approves CSL Behring’s IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of hemophilia B.

> Read More
29 February 2016 CSL Behring’s Long-acting rIX-FP for Hemophilia B - IDELVION® - Receives Positive Opinion from European Medicines Agency CHMP

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with hemophilia B.

> Read More
22 December 2015 CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A

Global biotherapeutics leader CSL Behring announced today that the company has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its novel investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In the pivotal clinical trial, rVIII-SingleChain met all primary endpoints.

> Read More
Page 2 of 19 First | Next | Last

Share
LinkedIn Twitter Facebook Google+